| Today's Top Story |  |  | | - Ipsen boosts neurology business with Syntaxin buy
Ipsen agreed to acquire Syntaxin, which specializes in recombinant botulinum toxins, for $36.5 million upfront plus as much as $169.6 million in milestone fees. The deal will grant Ipsen access to Syntaxin's lead product candidate, serenbotase, which is under development for post-herpetic neuralgia and overactive bladder with Allergan. "The acquisition of Syntaxin is a considerable addition to our neurology franchise and is fully aligned with our strategy of focus," Ipsen Chairman and CEO Marc de Garidel said. PharmaTimes (U.K.) (7/15), Genetic Engineering & Biotechnology News (7/15)       | Health Care & Policy | | | | - FDA issues penalty guidelines for drug inspection delays, obstacles
Draft guidance on penalties for drugmakers who deny access to inspectors and delay inspections was released Friday by the FDA. The draft relies on powers obtained from the FDA Safety and Innovation Act, which aims to guarantee the authenticity, proper shipping and distribution of drug products. The guidance defines various circumstances and actions that the agency will consider to be delaying, denying access or limiting inspections. MedPage Today (free registration) (7/12) - Does the clinical trial system need a reboot?
 Testing experimental drugs in broad groups is one of the main reasons that failure rates for clinical trials are so high, Clifton Leaf writes. Designing small clinical studies and enrolling only those with suitable genetic or molecular profile is a possible solution, but this approach could prove to be slow and arduous. The ongoing I-SPY 2 breast cancer trial, which includes multiple drugs and allows doctors to quickly glean information about which work best could be a good model to follow. Leaf is the author of "The Truth in Small Doses: Why We're Losing the War on Cancer" -- and How to Win It." The New York Times (tiered subscription model) (7/13) | Company & Financial News | | | | | Global Developments | | | | - China pricing probe mirrors action in other emerging markets
 Price premiums enjoyed by global drugmakers over local counterparts are at risk as governments in emerging markets clamp down on pharmaceutical costs. In addition to China's probe of 60 drugmakers, Turkey is enforcing cuts, Brazil is supporting local drugmakers, and India's relations with Western drugmakers have worsened. Reuters (7/12) | Food & Agriculture | | | | | Industrial & Environmental | | | | - Biomass-to-fuel project in Ore. picks technology provider
Red Rock Biofuels has chosen Oxford Catalysts Group to furnish the Fischer-Tropsch technology for a biofuel plant that it is building in Oregon. The biomass-to-liquids facility is expected to produce about 1,100 barrels daily of transportation fuels from biomass. The project is a recent recipient of a $4.1 million federal grant. DomesticFuel.com (7/15) | News from BIO | | | | - July 2013 BIO Therapeutic Newsletters
The BIO Emerging Companies Section Policy Team has compiled the latest news to keep you informed on the action in Washington with respect to the disease category on which your company is focused. Topics covered comprise: Allergy/Infectious Disease/Antiviral; Cardiology/Pulmonology/Blood; Nephrology/Endocrinology/Metabolism/Gastroenterology; Neurology/CNS; Oncology; and Rheumatology/Anesthesia/Inflammation/Pain. BIO has attempted to include updates from biotech stakeholders around Washington, including Congress, FDA, NIH and patient organizations. Access to our July 2013 Therapeutic Newsletters can be found here. Should you have any comments or questions, please contact Charles Crain.
| SmartQuote | | | |  | Whatever you do, do it with intelligence, and keep the end in view."
--Thomas à Kempis,
Dutch religious scholar  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, July 15, 2013
- Friday, July 12, 2013
- Thursday, July 11, 2013
- Wednesday, July 10, 2013
- Tuesday, July 09, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment